Literature DB >> 23643895

Cholesterol affects gene expression of the Jun family in colon carcinoma cells using different signaling pathways.

Eyal J Scheinman1, Ran Rostoker, Derek Leroith.   

Abstract

Hyperlipidemia and hypercholesterolemia have been found to be important factors in cancer development and metastasis. However, the metabolic mechanism and downstream cellular processes following cholesterol stimulation are still unknown. Here we tested the effect of cholesterol on MC-38 colon cancer cells. Using Illumina gene array technology we found a number of genes that were differentially expressed following short term (20-40 min) and longer term (between 2 and 5h) cholesterol stimulation. Three genes were consistently increased at these time points; c-Jun, Jun-B and the chemokine CXCL-1. We have previously shown that cholesterol stimulation leads to PI3K/Akt phosphorylation, and now demonstrated that cholesterol inhibits ERK1/2 phosphorylation; both effects reversed when cholesterol is depleted from lipid rafts using methyl-β-cyclodextrin (MBCD). In addition, vanadate, an inhibitor of phosphatases, reversed the cholesterol inhibition of ERK1/2 phosphorylation. Specific inhibition of p-Akt by wortmannin did not affect cholesterol's stimulation of the expression of c-Jun and Jun-B, however the vanadate effect of increasing p-ERK1/2, inhibited c-Jun expression, specifically, and the MBCD effect of increasing p-ERK and inhibiting p-Akt reduced c-Jun expression. In contrast MBCD and vanadate both enhanced Jun-B gene expression in the presence of cholesterol and elevation of ERK phosphorylation. Thus there is apparently, a differential signaling pathway whereby cholesterol enhances gene expression of the Jun family members.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23643895     DOI: 10.1016/j.mce.2013.04.011

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  6 in total

Review 1.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

Review 2.  Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.

Authors:  Emily Jane Gallagher; Derek LeRoith
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

Review 3.  Cholesterol, Oxysterols and LXRs in Breast Cancer Pathophysiology.

Authors:  Hassan Nazih; Jean Marie Bard
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

4.  Modulation of LXR signaling altered the dynamic activity of human colon adenocarcinoma cancer stem cells in vitro.

Authors:  Hassan Dianat-Moghadam; Mostafa Khalili; Mohsen Keshavarz; Mehdi Azizi; Hamed Hamishehkar; Reza Rahbarghazi; Mohammad Nouri
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

5.  CRMP4-mediated fornix development involves Semaphorin-3E signaling pathway.

Authors:  Benoît Boulan; Charlotte Ravanello; Sylvie Gory-Fauré; Jean-Christophe Deloulme; Amandine Peyrel; Christophe Bosc; Christian Delphin; Florence Appaix; Eric Denarier; Alexandra Kraut; Muriel Jacquier-Sarlin; Alyson Fournier; Annie Andrieux
Journal:  Elife       Date:  2021-12-03       Impact factor: 8.140

6.  Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma.

Authors:  Naoshad Mohammad; Parmanand Malvi; Avtar Singh Meena; Shivendra Vikram Singh; Balkrishna Chaube; Garikapati Vannuruswamy; Mahesh J Kulkarni; Manoj Kumar Bhat
Journal:  Mol Cancer       Date:  2014-09-01       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.